Navigation Links
Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs
Date:8/30/2013

MINNEAPOLIS/ST. PAUL (08/30/2013) A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).

The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy (IV).

The study, coauthored by Christine Clouser, Ph.D., Laurent Bonnac, Ph.D., Louis Mansky, Ph.D., and Steven Patterson, Ph.D., can be found "online first" in the journal Antiviral Chemistry & Chemotherapy.

"If you have a condition that requires you to take a medication everyday, as many patients with HIV do, you wouldn't want to have to take that medication via daily injection," said Steven Patterson, Ph.D., professor at the Center for Drug Design at the University of Minnesota. "This finding is a big step in demonstrating this treatment could be taken as a pill, similar to other HIV drugs, and is suitable for eventual clinical translation."

University of Minnesota researchers first announced decitabine and gemcitabine could potentially combine to treat HIV in research published in August 2010. The drug combination was shown to work by lethal mutagenesis that could obliterate HIV by causing the virus to mutate to a point where it was no longer infectious. For some patients, HIV's ability to quickly mutate and evolve can result in drug resistance. For patients who have developed resistance to currently available HIV treatments, the decitabine-gemcitabine drug combination could prove an effective alternative and secondary line of defense.

In addition to a potentially effective treatment for humans with HIV, the combination also shows potential to treat cats with leukemia.

"There's still a lot of work that needs to be done to demonstrate the safety and efficacy of this drug combination before human clinical trials can begin," said Patterson. "But we're optimistic that we're moving forward."


'/>"/>

Contact: Miranda Taylor
tayl0551@umn.edu
612-626-2767
University of Minnesota Academic Health Center
Source:Eurekalert

Related biology news :

1. Keck award enables Carnegie Mellon and Stanford to dramatically expand crowdsourced RNA design
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Research is ensuring stormwater systems are designed for the future
4. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
5. African scientist, designer partner to fashion anti-malaria garment that wards off bugs
6. Portable diagnostics designed to be shaken, not stirred
7. MIT-designed cooler preserves tuberculosis drugs, records doses
8. Progress in Osteoporosis re-launched with new design, now invites commentary
9. Faster, cheaper gas and liquid separation using custom designed and built mesoscopic structures
10. SACLA draws acclaim for unique XFEL design
11. A new type of data papers designed to publish online interactive keys identifying biodiversity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2019)... ... July 11, 2019 , ... ... today announced a partnership with LiquiTech, a leader in Legionella prevention for ... LiquiTech will integrate Spartan’s innovative environmental DNA testing platform to provide a ...
(Date:7/5/2019)... ... July 05, 2019 , ... SteriTrack Inc. is pleased ... to governments around the world. , Powered by Microsoft Azure, the Tractus™ ... solutions to operating theatres worldwide to address new global regulations mandating all medical ...
(Date:6/19/2019)... ... ... Dahryn Trivedi, today released research results on the beneficial impact of biofield ... be beneficial for treating multiple bacterial diseases. , The preclinical trial shows:, ... decrease in weight , Over 8% alteration in melting point ...
Breaking Biology News(10 mins):
(Date:5/21/2019)... , ... May 21, 2019 , ... ... Berlin (VLB) today officially opened the inaugural Africa Brewing Conference dedicated to sharing ... industry in Africa. The event, which is supported through a partnership with “Ethiopia ...
(Date:5/14/2019)... ... May 13, 2019 , ... ... leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ ... The redesigned website aims to improve LDA’s ability to communicate directly with the ...
(Date:5/7/2019)... British Columbia (PRWEB) , ... May 06, 2019 ... ... be a go-to resource for the growing number of repositories being asked to ... We are grateful to the team of contributors who are world leaders, who ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... Organization for Standardization ISO 9001:2015 standard, REPROCELL USA Inc. has demonstrated its ... In addition, REPROCELL USA Inc. aims to enhance customer satisfaction through the ...
Breaking Biology Technology: